![]() |
市场调查报告书
商品编码
1452997
全球凝块管理设备市场 2024-2031Global Clot Management Devices Market 2024-2031 |
预计在预测期内(2024-2031 年),全球凝块管理设备市场将以 7.3% 的CAGR成长。血栓管理装置对于治疗危及生命的疾病(例如 DVT 和 PE)以及随后的经皮冠状动脉介入治疗、去除或溶解动脉中的血栓以及恢復血液循环至关重要。
市场动态
Global Clot Management Devices Market Size, Share & Trends Analysis Report by Products (Embolectomy Balloon Catheter, Catheter Directed Thrombolysis Devices, Percutaneous Thrombectomy Devices, Inferior Vena Cava Filters, Neurovascular Embolectomy Devices, and Others), and by End-User (Ambulatory Surgical Centers (ASCs), Diagnostic Centers, and Others) Forecast Period (2024-2031)
Global clot management devices market is anticipated to grow at a CAGR of 7.3% during the forecast period (2024-2031). Clot management devices are essential for treating life-threatening conditions such as DVT and PE subsequently percutaneous coronary intervention, removing or dissolving clots from blood arteries, and restoring blood circulation.
Market Dynamics
Increase in the Elderly Population
Growing older raises the risk of conditions such as deep vein thrombosis (DVT), which can cause a fatal pulmonary embolism and other consequences. DVT is prevented via the use of clot management devices, such as superior vena cava filters. The growing number of older individuals can boost demand for these devices and fuel the expansion of the clot management devices market. According to the National Institute of Health ( gov.), in November 2023, as per the report, World Health Organization's Decade of Healthy Ageing report predicts a 34% increase in older adults aged above 60 globally, from 1 billion in 2019 to 1.4 billion in 2030. Furthermore, Cardiovascular diseases are the leading cause of global death, causing 32% of all deaths in 2019. In 2019, 17.9 million people died, with 85% owing to heart attacks and stroke. Preventive measures include addressing risk factors and early detection for effective management.
Increased Risk of Thrombotic Incidents in HIV/AIDS Patients
Although utilizing c-ART, HIV/AIDS patients have a higher risk of thrombotic events, such as VTE, owing to endothelial dysfunction, immunological activation, and inflammation. According to the National Institute of Health (gov.) in May 2023, despite the use of combination antiretroviral therapy (c-ART), HIV/AIDS continues to cause 1.7 million new cases and 690 thousand deaths annually, posing a significant economic and medical threat to human health. Patients with HIV are at a higher risk of non-HIV/AIDS causes of end-organ disease, including vascular complications like VTE.
Market Segmentation
Neurovascular Embolectomy Devices are Projected to Emerge as the Largest Segment
Based on the product, the Clot Management Devices market is sub-segmented into embolectomy balloon catheters, catheter-directed thrombolysis devices, percutaneous thrombectomy devices, inferior vena cava filters, neurovascular embolectomy devices, and others. Among these, the neurovascular embolectomy devices sub-segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes the increasing demand for the prevalence of hypertension in low- and middle-income nations renders it necessary to implement effective management strategies, such as increasing awareness, enhancing screening, and encouraging blood pressure control. These measures additionally fuel the demand for devices for neurovascular embolectomy and clot management. According to the World Health Organisation, in March 2023, Hypertension affects 1.28 billion adults aged 30-79, primarily in low- and middle-income countries. 46% are unaware, 42% are diagnosed, and 21% have it under control. The global target is to reduce hypertension prevalence by 33% between 2010 and 2030.
Hospitals and Clinics Sub-segment to Hold a Considerable Market Share
Hospitals collaborate with industry partners, such manufacturers of clot management devices, to deploy innovative solutions such as blood clot applications, accelerating the adoption of healthcare programs. For instance, in November 2023,Oxford University Hospitals launched blood clot app. To inform individuals regarding blood clots and methods for lowering risk.The new app integrated into patients' discharge and admission documents, advising them to seek medical attention for severe blood clot symptoms.
The global clot management devices market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America).
Increased demand for Public Health Programs in Asia-Pacific
North America Holds Major Market Share
Among all the regions, North America holds a significant share owing to the transportation services such as Clot Management Devices are required for the moving of coal owing to the patient advocacy groups play an essential role in promoting VTE awareness, fighting for easier access to clot management tools and therapies, and funding projects that can improve the care of individuals with VTE. According to the National Institute of Health (gov.) in March 2022, the incidence of venous thromboembolism (VTE) in the U.S. is currently estimated to be between 71 and 113 cases per 100,000 population. Deep vein thrombosis occurs in approximately 200,000 patients annually, with approximately 50,000 cases complicated by pulmonary embolism. The incidence of pulmonary embolism is 1-2 per 1,000 person-years, and more than a third of survivors experience recurrence. It is important to note that VTE-related events contribute to a higher number of deaths compared to AIDS, breast cancer, prostate cancer, and motor vehicle crashes combined in the US.
The major companies serving the global clot management devices market include, Boston Scientific Corp.,Edwards Lifesciences Corp.,Medtronic PLC,Penumbra, Inc.,Teleflex Inc., and others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance, in September 2020, Philips introduced the Azurion neuro biplane system at ECR2024, enhanced minimally invasive diagnosis and treatment of neurovascular patients, providing image-guided therapy for confident diagnosis and assessment.